



INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known			
		Application Number	10/677,967		
		Filing Date	October 2, 2003		
		First Named Inventor	Anke Esperester et al		
		Art Unit	1614		
		Examiner Name	To be assigned		
Sheet	1	of	1	Attorney Docket Number	1/1556

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
2 ↓ 2		MONTANDON J.B. ET AL; In-Vitro versus in-vivo activities of new 5-Lipoxygenase Inhibitors with Antiinflammatory Activity; Int. J. Tissue Reac. Vol. 11 No. 3 pages 107-112 (1989); Bioscience Ediprint Inc.	
		PIETRO GHEZZI ET AL; Differential Contribution of R and S Isomers in Ketoprofen Anti-Inflammatory Activity: Role of Cytokine Modulation 1; The Journal of Pharmacology and Experimental Therapeutics Vol. 287 No. 3 pages 969-974 (1998); The American Society for Pharmacology and Experimental Therapeutics	
		MASAYUKI AIHARA ET AL; Effects of N-Acetylcysteine and Ambroxol on the Production of IL-12 and IL-10 in Human Alveolar Macrophages; Respiration (2000) Vol. 67 pages 662-671; Karger AG Basel	
		M. BIANCHI ET AL; Ambroxol inhibits interleukin 1 and tumor necrosis factor production in human mononuclear cells; Agents and Actions (1990) Vol. 31 pages 275-279; Birkhauser Verlag. Basel	
		S. PFEIFER ET AL; Reduction of Cytokine Release of Blood and Bronchoalveolar Mononuclear Cells By Ambroxol; European Journal of Med. Res. (1997) Vol. 2 pages 129-132; I. Holzapfel Publishers	

Examiner Signature		Date Considered	1/8/07
-----------------------	--	--------------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.